Best Practices for POTS Clinical Trials
- Apr 19
- 7 min read
Updated: 5 days ago
An Autonomic Field Guide for Research Teams and Patient-Centered Organizations
By Cynthia Adinig
Key Findings and Summary
POTS clinical trials often fail to produce consistent, real-world outcomes because they treat POTS as a narrow cardiovascular condition rather than a heterogeneous, multi-system disorder. Contemporary literature characterizes POTS as a syndrome involving autonomic dysfunction, fatigue, cognitive impairment, gastrointestinal symptoms, and significant quality-of-life burden (Raj et al., 2020; Steinberg et al., 2023). This paper identifies core structural gaps in POTS research, including shallow phenotyping, inadequate endpoint selection, failure to capture symptom variability, and limited use of adaptive trial design. It proposes a CYNAERA-aligned framework centered on stabilization, subtype stratification, longitudinal monitoring, and patient-centered outcomes.
Key recommendations include:
Prioritizing stabilization before escalation
Stratifying participants by autonomic and symptom phenotype
Using endpoints that reflect orthostatic tolerance and functional recovery
Integrating wearables and digital biomarkers
Using simulation modeling to reduce trial failure
1. Stabilization and Functional Capacity, Not Just Heart Rate
POTS is defined by orthostatic intolerance with excessive heart-rate increase, but its clinical burden extends far beyond tachycardia. Patients commonly experience fatigue, cognitive dysfunction, sleep disturbance, gastrointestinal symptoms, and reduced functional capacity (Raj et al., 2020; Arnold et al., 2018).
Define success using patient-centered outcomes such as improved upright tolerance and daily function
Treat stabilization as a meaningful early endpoint
Avoid equating heart-rate normalization with clinical recovery
2. Deep Screening for Phenotypes and Comorbid Conditions
POTS is a heterogeneous syndrome with multiple contributing mechanisms, including neuropathic, hyperadrenergic, hypovolemic, autoimmune-associated, and post-infectious subtypes (Raj et al., 2020; Vernino et al., 2018; Steinberg et al., 2023).
Participants should be screened and stratified for:
Hemodynamic subtype (neuropathic, hyperadrenergic, hypovolemic)
Post-viral or post-infectious onset
Hypermobility or connective tissue features
Migraine, gastrointestinal dysfunction, and sleep disturbance
Overlap with ME/CFS, MCAS, and small fiber neuropathy
Failure to account for this heterogeneity leads to inconsistent outcomes and reduced interpretability (Raj et al., 2020; Steinberg et al., 2023).
3. Design a Multi-Stage, Adaptive Trial Architecture
Rigid trial designs fail to capture the variability of POTS. Adaptive designs allow protocols to respond to patient-level differences.
Stage 1: Stabilization
Fluid and salt optimization
Compression and pacing strategies
Sleep and trigger stabilization
Baseline establishment through run-in periods
Stage 2: Targeted Intervention
Phenotype-specific therapeutic arms
Medication, autonomic support, or rehabilitation strategies
Adaptive adjustments based on response (FDA, 2019; FDA, 2024; Kaizer et al., 2023)
Stage 3: Maintenance and Relapse Prevention
Monitor durability of response
Track symptom rebound after exertion, heat, or stress
Use flexible stopping rules to protect participants
4. Use Endpoints That Reflect Real-World Orthostatic Behavior
Traditional endpoints often fail to capture the lived experience of POTS, which includes orthostatic intolerance, fatigue, cognitive dysfunction, and functional impairment (Raj et al., 2020; Arnold et al., 2018).
Primary endpoints
Sustained improvement in orthostatic tolerance
Reduction in symptom burden during standing
Improved functional capacity and daily activity
Secondary endpoints
Heart-rate response and recovery patterns
Presyncope fr23equency and severity
Cognitive function, fatigue, and sleep
Quality of life and participation in work or school
5. Integrate Exercise Carefully and Respect Exertional Limits
Exercise training has demonstrated benefit in some POTS populations, but outcomes depend heavily on program design and patient selection (Fu et al., 2011; Fu and Levine, 2018; George et al., 2016).
Avoid uniform exercise prescriptions
Use staged or recumbent programs where appropriate
Monitor delayed symptom worsening
Stratify patients with fatigue-dominant or PEM-like features
6. Integrate AI, Wearables, and Digital Biomarkers
POTS is well suited to continuous physiologic monitoring due to symptom fluctuation across posture, hydration, activity, and environmental exposure.
Track heart rate, sleep, activity, and recovery
Capture real-time symptom variability
Identify flare patterns using machine learning
Use longitudinal dashboards rather than episodic visits
Wearable biosensors and digital health tools are increasingly recognized as valuable for capturing physiologic variability over time (Li et al., 2017; Dunn et al., 2018; Kaizer et al., 2023).
7. Use Simulation Modeling Before Trial Launch
Trial failure in POTS is often driven by heterogeneity, symptom variability, and dropout.
Model subtype distribution before recruitment
Simulate endpoint sensitivity and variability
Anticipate dropout and adherence challenges
Optimize trial arms prior to enrollment
Simulation and modeling approaches improve trial efficiency and interpretability (Ioannidis, 2016; Kaizer et al., 2023).
8. Engage Ethical Oversight with Patient Representation
POTS patients frequently experience delayed diagnosis and dismissal, making ethical design critical.
Include patient advocates in trial design and oversight
Allow accommodations for orthostatic intolerance
Reduce burdensome in-person requirements
Use clear and accessible consent processes
Patient-centered approaches improve recruitment and retention (Raj et al., 2020).
9. Plan for Real-World Uptake and Scalability
POTS care varies widely across healthcare systems and clinical settings.
Design protocols adaptable to primary and specialty care
Include non-pharmacologic and combination approaches
Ensure monitoring tools are accessible
Plan for both pediatric and adult populations
Scalable approaches improve translation from research to practice (Raj et al., 2020; Steinberg et al., 2023).
10. Document Heterogeneity and Preserve Negative Findings
POTS research is limited by inconsistent reporting and masked subgroup effects.
Report subgroup-specific outcomes
Publish negative findings
Document variability in response
Maintain transparent methodology
Transparent reporting strengthens cumulative knowledge and prevents repeated failure (Ioannidis, 2016).
Why Traditional POTS Trials Fail
Traditional POTS trials fail when they reduce a heterogeneous autonomic syndrome to a narrow cardiovascular endpoint. Many studies overemphasize heart-rate reduction while underrepresenting fatigue, cognition, and functional impairment (Raj et al., 2020; Steinberg et al., 2023). They also rely on static measurements despite dynamic symptom patterns influenced by posture, hydration, exertion, and environmental factors. This limits the ability to detect meaningful clinical change. Finally, inadequate stratification and failure to account for overlapping conditions lead to mixed results that obscure true treatment effects (Vernino et al., 2018; Steinberg et al., 2023).
Summary
POTS trials succeed when they recognize heterogeneity, incorporate adaptive design, and prioritize patient-centered outcomes. Integrating longitudinal monitoring, subtype stratification, and real-world endpoints improves both scientific validity and clinical relevance (Raj et al., 2020; Steinberg et al., 2023). These gaps are further explored through The Eve Research Project, an ongoing research program capturing real-world patient data across hormonal life stage, immune activity, and environmental exposure. The findings highlight how current clinical trials often fail to account for variability in disease expression, leading to inconsistent outcomes across key patient populations.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Arnold, A.C., Ng, J., Raj, S.R. (2018) ‘Postural tachycardia syndrome: diagnosis, physiology, and prognosis’, Autonomic Neuroscience, 215, pp. 3–11.
Dunn, J., Runge, R., Snyder, M. (2018) ‘Wearables and the medical revolution’, Personalized Medicine, 15(5), pp. 429–448.
FDA (2019) Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. U.S. Food and Drug Administration.
FDA (2024) Interacting with FDA on Complex Innovative Trial Designs. U.S. Food and Drug Administration.
Fu, Q., Vangundy, T.B., Shibata, S., et al. (2011) ‘Exercise training versus propranolol in POTS’, Hypertension, 58(2), pp. 167–175.
Fu, Q., Levine, B.D. (2018) ‘Exercise and non-pharmacological treatment of POTS’, Autonomic Neuroscience, 215, pp. 20–27.
George, S.A., Bivens, T.B., Howden, E.J., et al. (2016) ‘Exercise training in POTS’, Journal of the American College of Cardiology, 67(24), pp. 2856–2858.
Ioannidis, J.P.A. (2016) ‘Why most clinical research is not useful’, PLoS Medicine, 13(6).
Kaizer, A.M., Koopmeiners, J.S., Long, J.D. (2023) ‘Adaptive trial design methods’, Current Epidemiology Reports.
Li, X., Dunn, J., Salins, D., et al. (2017) ‘Digital health and wearable biosensors’, PLoS Biology, 15(1).
Raj, S.R., Guzman, J.C., Harvey, P., et al. (2020) ‘Canadian Cardiovascular Society position statement on POTS’, Canadian Journal of Cardiology, 36(3), pp. 357–372.
Steinberg, R.S., et al. (2023) ‘Narrative review of POTS’, Frontiers in Neurology.
Vernino, S., Bourne, K.M., Stiles, L.E., et al. (2018) ‘Autoimmune mechanisms in POTS’, Autonomic Neuroscience, 215, pp. 78–82.
Comments